Placebo trials without mechanisms: How far can they go? by Teira, David
1 
 
PLACEBO TRIALS WITHOUT MECHANISMS: HOW FAR CAN THEY GO? 
David Teira 
Dpto. de Lógica, Historia y Filosofía de la ciencia, UNED 
Senda del rey 7 | 28040, Madrid (Spain) 
dteira@fsof.uned.es 
 
Published in Studies in History and Philosophy of Biol & Biomed Sci, 
https://doi.org/10.1016/j.shpsc.2019.101177 
 
ABSTRACT 
In this paper, I suggest that placebo effects, as we know them today, should be understood 
as experimental phenomena, low-level regularities whose causal structure is grasped 
through particular experimental designs with little theoretical guidance. Focusing on 
placebo interventions with needles for pain reduction -one of the few placebo regularit ies 
that seems to arise in meta-analytical studies- I discuss the extent to which it is possible 
to decompose the different factors at play through more fine-grained randomized clinica l 
trials. My sceptical argument is twofold. On the one hand, I argue that experiments alone 
are not enough to standardize interventions, and that it is necessary to include theories.  
On the other hand, I argue that the social interactions that seem to be part of placebo 
effects are difficult, if not impossible, to blind. Therefore, the measurement biases arising 
from the participants’ reactivity to the experimental setup cannot be controlled for.  
Further decomposition of placebo effects requires a theoretical account of the existing 
experimental regularities that may guide further tests. 
Keywords: placebo; clinical trials; reactivity; needling; mechanisms; standardization 
1. Decomposing placebo interventions 
Over the last fifty years, the experimental social sciences have created a catalogue 
of phenomena, regularities that arise from the data accumulated in a family of 
experiments (Bogen & Woodward, 1988; Guala, 2005, pp. 41-44). These tests aim at 
capturing and describing the details of a prima facie causal structure, with or without the 
support of a pre-existing theory. Experimentalists may look for phenomena guided by a 
theory that may explain them, but phenomena can be also freestanding regularit ies 
awaiting an explanation or further analysis1. For instance, the regularities emerging from 
the popular dictator game in experimental economics (a test about how people share 
resources) can be appraised as a test of the predictions of economic theory about 
                                                                 
1 (Gervais & Weber, 2015) discusses how these regularities often emerge from what they aptly call 
orientation experiments, in which experimenters, often without a guiding theory, offer a rough, qualitative 
characterization of the mechanism responsible for a salient causal capacity.  
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individual decisions, but also as an independent experimental setup for investigating all 
sort of sharing behaviours (Jiménez-Buedo, 2015).  
The placebo effect in medicine often appears as one such phenomenon. It 
originated in informal observations that led to a collection of systematic experiments, all 
of which showed how treatments without, e.g., a pharmacologically active principle had 
nonetheless measurable therapeutic benefits. Placebo effects have a freestanding status in 
medicine: they have been documented almost without theoretical guidance and still today 
there is no consensual account explaining why placebos work. In this regard, as I will 
argue in section 2, the status of placebo effects as phenomena has been linked to an 
experimental method to capture them, in particular the randomized clinical trial (RCT). 
During the second half of the 20th century, many different interventions were tested in 
RCTs for placebo effects with often positive outcomes.  
All these outcomes have been challenged from the 1980s onwards (Kienle & 
Kiene, 1997) when a statistical reanalysis of the raw data showed how the purported 
phenomenon was most likely a statistical artefact: a simple regression to the mean 
(McDonald, Mazzuca, & McCabe, 1983). Under certain statistical assumptions, it can be 
shown that, on average, patients exhibiting abnormal levels of an outcome variable (such 
as pain) will regress to the mean level, whatever the treatment they receive: if the patients’ 
pain was abnormally high, it will decrease; if it was abnormally low, it will increase. A 
recent Cochrane review (Hrobjartsson & Gotzsche, 2010) found that placebo 
interventions had no relevant clinical effects, except for patient reported outcomes, 
especially when using physical devices (such as needles) for pain reduction –pace 
(Howick, 2017).  Interventions without a clear causal pathway such as acupuncture can 
relieve the self-reported degree of pain in patients, according to a standardized scale, by 
a clinically relevant magnitude. 
In other words, the placebo effect would only constitute a real experimenta l 
phenomenon for a particular class of interventions on just an outcome variable: roughly 
speaking, placebo physical devices for pain reduction. Taking this as my starting point, I 
discuss the possibility of decomposing the only placebo effect so far documented into 
further components through new experimental designs. The general question I want to 
address is whether more clinical trials can lead to the discovery of new regularities about 
placebos or it is rather time for basic research to pave the way for further experimentat ion. 
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The social and biomedical sciences have witnessed throughout the last five years how 
many experimental phenomena have not resisted the test of systematic replication 
(Fanelli, Costas, & Ioannidis, 2017). In this context, this paper is a reflection on the limits 
of the experimental decomposition of a complex causal structure, the placebo effect, 
involving social and biomedical factors. Are clinical trials enough to grasp the factors at 
play in placebo effects?  
My case in point is a particularly insightful trial design: (Kaptchuk, et al., 2008) 
investigated whether a placebo effect could be triggered by three different interventions  
that had been merged in previous tests. The interventions were assessment and 
observation, “a therapeutic ritual”, and a supportive patient-practitioner relationship. The 
trial targeted patients with irritable bowel syndrome (IBS)2: in the first arm, the 
participants were put on a waiting list (observation); in the second arm, the participants 
received sham acupuncture administered by a therapist with a sober interaction script; in 
the third arm, sham acupuncture was administered with an engaging interaction script in 
which the therapist showed active support for the patient. The effects of these 
interventions were assessed with four patient-reported outcomes, and the statistica l 
analysis showed that sham acupuncture either with a limited or an augmented interaction 
produced statistically and clinically significant outcomes. The three interventions, the 
authors concluded, “can be progressively combined in a manner resembling a graded dose 
escalation of component parts” (Kaptchuk, et al., 2008).  
My question in this paper is whether these factors can be further decomposed in 
subsequent trials.  In order to answer it, I will proceed as follows. In the following section, 
I will explain in what sense RCTs capture a regularity in placebo effects and what sort of 
phenomenon we are witnessing in the IBS trial. In sections 3 and 4, I will discuss the two 
interventions in the trial, needling and interaction scripts. I will defend that experiments 
alone do not allow us to standardize these interventions to the degree that it would be 
necessary for a more fine-grained study of placebo analgesia. This lack of standardizat ion, 
I will contend, is the source of the high heterogeneity and poor outcomes in so many 
experiments on needles and social scripts. Only basic research on the underlying 
mechanisms of placebo will allow trials to obtain further regularities about placebos.  This 
may not be a popular conclusion in a field that has built until recently on the accumula t ion 
                                                                 
2 From now on, I will refer to (Kaptchuk, et al., 2008) as the IBS trial.  
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of simple empirical regularities, but, as I will argue in the conclusion, it is the better option 
to overcome the crisis of confidence in blind experimental research. 
2. Measuring placebos in RCTs 
The first step in my argument will be to explain in what sense the placebo effect 
has been, at most, an experimental phenomenon – one in which the causal structure did 
not arise from any theory but rather from the very design of the experiment. Historians of 
the placebo effect usually refer to the tests conducted by the Franklin commission in 1784 
as the first experimental study of the placebo effect (Teira, 2016). At the request of the 
French monarchy, the commission had to assess the efficacy of J.B. Mesmer’s magnetic 
therapy. Among its members there was Antoine Lavoisier, the great chemist, who 
systematized the use of blinding for the causal analysis of medical treatments. Lavoisier 
suspected that there was no real connection between the treatment and the effects 
observed in patients. He disentangled both following the standard laboratory practice of 
chemist: analysis and synthesis: 
There is only one way to achieve it: demagnetize the more sensitive persons 
without their awareness, and persuade them of being magnetized when they 
actually aren’t. Gathering these two types of experiments, we will obtain 
separately the effects of magnetism and those of imagination, and we will be able 
to conclude what we should attribute to each one of them. (Lavoisier, 1865) 
Lavoisier installed a screen between the therapist and the patient, so that this latter 
could not tell whether an intervention was being performed. Mesmer was discredited 
when, blinded, patients did not exhibit any of the effects of the therapy administered.  
From then on, blinding became a standard control in clinical trials, probably in response 
to an already widespread intuition among physicians: the mental states of patients 
(Lavoisier’s “imagination”) played some sort of role in their recovery. Blinding was 
therefore the device that allowed experimenters to decompose the different factors 
contributing to a treatment effect, without an actual understanding of their causal 
mechanisms.  
Lavoisier showed that the therapeutic role of “imagination” could be isolated in 
an experimental setup through blinding. But it took 150 years more to quantify the 
placebo effect and transform it into a phenomenon (Miller, Colloca, & Kaptchuk, 2013) 
For this, we need to measure the differences between treatments in order to ascertain their 
degrees of efficacy. RCTs made this measurement possible. RCTs became a standardized 
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experimental design for testing treatments in the 1940s and the 1950s, articulating the 
statistical foundations laid by Ronald Fisher the previous decade with a long-stand ing 
tradition of controls in medical tests. RCTs are comparative experiments: at least two 
interventions are administered to two groups of patients, measuring the respective effects. 
If any difference in the outcome is observed, the design of the experiment will allow us 
to assess whether it is statistically significant and, if so, whether it is big enough for 
patients to benefit. 
RCTs implement John Stuart Mill’s method of difference in causal analysis: the 
two groups should be entirely alike except for the intervention administered. Hence, if 
there is a difference between the treatment effects, we will be entitled to attribute it to the 
causal power of each treatment. However, in every other respect, RCTs operate as a 
causal black box: we focus on the size of the difference between treatment outcomes, 
abstracting away the causal mechanisms by which such effects occur. Throughout the 
drug development process, researchers might have learnt about these mechanisms 
reasonably well. But success in a RCT depends only on the difference between treatment 
outcomes, independently of how good our mechanistic understanding of these outcomes 
is. Still in the 1950s and 1960s, treatments reached the pharmaceutical markets without 
such causal understanding of their action (Gonzalez-Moreno, Saborido, & Teira, 2015). 
The placebo effect was quantified through RCTs in this black-boxed manner : 
without any assumption about the mental states involved, it was possible to quantify the 
effect of a placebo intervention in an arm of the trial and compare it to the outcome of the  
other treatments administered (or lack of them). We speak of the placebo effect when 
there is statistically significant difference between the outcome of a placebo intervention 
and the outcome of a no treatment group. However, in order to reach clinical significance 
(i.e., actual benefit for a patient), the placebo should not be worse than the standard 
treatment. As in every other RCT, treatments are not assessed on themselves but always 
regarding a clinical consensus on the appropriate intervention (or a placebo, if there is 
none). 
A great deal of controversy on the placebo effect hinges on the diversity of 
experimental approaches to capture it. The last seven decades have witnessed all sorts of 
tests documenting placebo effects: apart from RCTs, there are experiments on animals, 
behavioural analysis, studios of brain images and physiological responses, etc. –see 
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(Miller, et al., 2013) for a survey. This wealth of evidence would suggest that placebo  
effects are a well-consolidated phenomenon. Therefore the paradox in the results of 
(Hrobjartsson & Gotzsche, 2010) meta-analysis: if only physical interventions on pain 
measured via subjective reports cause statistically significant effects, how shall we 
interpret all the other evidence about placebos? Here is where the concept of phenomenon 
plays a clarificatory role. Until a theory emerges to provide a unified explanation of all 
the placebo phenomena, what we actually have is a collection of experimenta l 
regularities, each one of them emerging from a particular setup. In these setups, the 
phenomenon will only exist to the extent that it is replicable: experimenters can reproduce 
it at will. Although placebo experiments often target similar variables (pain, expectations, 
etc), there is no reason to consider all the emerging regularities as instantiations of the 
same phenomenon. This is something only theories do, and there is still no consensual 
theoretical account of placebos (Miller, et al., 2013).  
Why then focusing on RCTs as the locus of placebo effects? A more or less 
implicit assumption in placebo literature is that placebos are significant phenomena to the 
extent that they have significant clinical effects. The benchmark for what counts as one, 
for the last seventy years, has been the RCT: only to the extent that placebo interventions 
show efficacy under the same conditions as standard treatments will they count as 
conventional therapies –instead of, e.g., alternative medicine. If RCTs successfully track 
a regularity connecting placebo interventions with clinically relevant effect, this 
phenomenon is enough to consider placebo a medicine on equal grounds with other 
successful drugs that were accepted as such without a full understanding of their causal 
mechanisms. 
From all this I draw two assumptions for the rest of my analysis. On the one hand, 
the placebo effect as an experimental phenomenon has its most interesting expression for 
therapeutic purposes in RCTs. On the other hand, the only solid placebo phenomenon 
documented RCTs occurs with physical devices to treat pain with a patient reported 
outcome. The available evidence suggests that there is something special to the placebo 
effects caused by, e.g,, needling and the question I want to address is whether more 
sophisticated RCT designs are enough to disentangle the active principle behind such 
interventions. The beauty of the IBS trial (Kaptchuk, et al., 2008) is that it takes exactly 
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this approach and uses a brilliant design in order to tear apart the components of the 
placebo effect in an RCT setup3. 
The treatment arms address three potential ingredients of this effect: the patients' 
response to observation and assessment (being in a waiting list); the patients’ response to 
a perceived physical intervention (sham acupuncture); and the patients’ response to this 
latter augmented with a positive interaction with the therapist (sham acupuncture plus a 
scripted conversation). The trial’s causal box remains black: we may safely ignore the 
mechanism underlying the three interventions. But the size of the box is reduced: the 
placebo effect is disentangled, thanks to the patients’ blinding. To the extent that they 
actually ignore the goal of the trial and the actual intervention being performed, their 
differential responses will show the size of each component of the placebo effect. The 
trial showed that these three components add up progressively, reaching a maximum 
effect with the augmented placebo, reaching a clinically significant effect in the treatment 
of the condition. The outcome variable was a patient reported outcome (the IBS Global 
improvement scale) which asked patients about the improvement of their symptoms. 
These are usually abdominal pain and discomfort associated with altered bowel habits. 
The authors of the IBS trial are clearly aware that the three ingredients under study 
are big enough to encompass many different factors. As we will later discuss in section 
4, it is impossible to rule out in this trial setup that the outcome owes much to the patients’ 
reactivity: the patients are behaving in the test in a way that owes more to the interaction 
with the experimenter than to their own spontaneous reactions to the interventions.  
Following Kaptchuk’s approach (Kaptchuk, 2002; Kerr, et al., 2011), the placebo 
treatment would capture the patient’s response to the administration of a therapeutic 
ritual, for which the list of sub-ingredients is not short: the characteristics of both patient 
and practitioner, their interaction, the nature of the illness treated and the very treatment 
and treatment setting. The latter two arms will pick up on two of these sub-ingredients : 
the patient-practitioner interaction and the (purported) treatment. 
The question the IBS trial opens is: how much deeper can we go into the 
decomposition of these different ingredients in the placebo effect through more fine-
grained RCTs? Is it possible to unbundle the different elements in each arm into more 
                                                                 
3 I will assume, for the sake of the argument, that the IBS is indeed a replicable regularity. My argument 
does not presuppose it though: lack of reproducibility could be easily explained precisely for the causal 
roughness of the interventions tested, as discussed in sections 3 and 4. 
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specific interventions so that the different placebo components are more clearly 
identified? Although these are empirical questions that only further experiments will 
settle, I want to argue that experiments alone are not enough to standardize the two 
interventions under study at the IBS trial. At least, not to the degree required to obtain a 
solid replicable regularity. Let me start with needles in section 3 and then proceed to 
interaction scripts in section 4. 
3. On the necessity of treatment standardization: needles 
Testing a treatment in a clinical trial requires a certain degree of standardizat ion. 
RCTs test a hypothesis about the comparative efficacy of, at least, two interventions. The 
statistical design of most RCTs assume a frequentist interpretation of probability. A p-
value is the probability of observing a range of trial outcomes (under the hypothesis of no 
difference between treatments) if the RCT was repeated time and again. In a frequentist 
approach, the probabilistic assessment of a trial outcome is then tied to a particular 
experimental design: if the experiment is impossible to repeat, probabilities like p-values 
stop making sense. If an RCT can be repeated and outcomes appear with the initia l ly 
predicted frequency, it is a sign of experimental control of the intervention under study 
(Spanos & Mayo, 2015). Under certain assumptions (Norton, 2015), the replicability of 
an experiment suggests that the intervention has a causal structure that does not depend 
on the particular characteristics of the experimenter: anybody following the protocol can 
obtain the same outcomes. 
Therefore, if RCTs are adopted as the yardstick test of safety and efficacy, 
therapeutic interventions should be standardized enough to allow for direct replication. 
Pharmacological interventions easily meet this degree of standardization. On the one 
hand, they are industrially produced with strict quality control procedures. On the other 
hand, the administration instructions for most drugs can be easily summarised in a simple 
brochure. RCTs have been particularly successful at testing pharmaceutical compounds, 
but not so much in the assessment of less standardized interventions, such as surgical 
procedures. The development of surgical techniques involves a continuous refining 
process (Wartolowska, et al., 2016) in which a procedure is improved through gradual 
and constant modifications. Surgical degrees rarely remain the same and RCTs are rare 
and often have no significant impact on surgical praxis (Wartolowska, et al., 2014). 
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Drawing on these premises, my argument in this section will be as follows. So far, 
the only placebo effects with clinical and statistical significance have been obtained with 
needling techniques for treating subjectively reported pain. The IBS trial provides a 
decomposition of the factors at play in these interventions. I am going to argue next that 
any further decomposition requires a clinical trial design that controls for the two sources 
of measurement error that most often appear in assessing pain relief interventions. This 
trial design requires a degree of standardization in the interventions that experiments 
alone on neither needling nor scripting can yield. In this section, I will make the case for 
needling, leaving the analysis of interactions scripts for the following one. 
Since standardization is often a matter of degree, let me first explore which 
particular degree is necessary for testing any intervention for pain relief, following 
(Dworkin, McDermott, Farrar, O'Connor, & Senn, 2014).  First, regarding pain our 
species is not a homogenous biological population: not all patients are equally responsive 
to treatment, be it because of genetic differences in pain perception or in analgesic 
responses (Lotsch & Geisslinger, 2006; Mogil, 2012). Therefore, depending on the 
patient, the treatment effect might be systematically bigger or smaller, i.e. not random 
variations around the mean. Focusing on the mean treatment effect averaged over all 
patient potentially misses clinically relevant differences in response between patients. 
Measuring this potential treatment-by-patient interaction in an RCT requires a multip le-
period-cross over design, in which each patient receives each treatment tested in the trial 
in at least two different periods. This would be, for instance, a 4-period cross-over trial 
with 2 periods of active treatment and 2 periods of placebo (Dworkin, et al., 2014). Taking 
up again the IBS trial interventions, in order to measure the treatment-by-patient 
interaction regarding the interaction script, each patient should receive both sham-
acupuncture without the positive script and sham-acupuncture augmented with the 
positive script, in two different rounds. This would allow us to detect whether the 
sensitivity to the script varies between patients. At the same time, this multiple-period-
cross-over design would allow us to grasp the potential within-patient variation over time: 
the measured outcome may also vary depending on the different responses a patient may 
give to the same treatment in different treatment periods. For instance, a potential source 
of variation is the lack of consistency between a single patient’s responses, when she is 
asked to report her pain reduction in response to the same treatment. Even when patients 
use a standardized score to grade the analgesic effects of the treatment, they often assess 
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it differently in different exposures to the same intervention. This is a source of error to 
be controlled for whenever subject-reported outcomes are used, as it often happens in 
placebo trials on pain (Hrobjartsson & Gotzsche, 2010).  
Multiple period cross-over designs allow us to measure these two sources of 
variability but they are, of course, complicated to implement and there are not many 
available in the pain literature (Dworkin, et al., 2014, p. 458). Yet, from a methodologica l 
standpoint, if we are to advance in the decomposition of the placebo effect through 
clinical trials, this particular cross-over design seems the most adequate option. On the 
one hand, there are clear signs of placebo treatment per patient interactions: although 
there is no precise identification of the placebo responder in terms of personality traits 
(Kaptchuk, 2002), there is evidence enough about placebo responses varying with 
individual patient’s expectations (Kirsch & Rosadino, 1993; Price, et al., 1999). The 
formation of these expectations is a clear target for experimental decomposition. On the 
other hand, as we already saw, placebo effects have been shown to originate in simple 
statistical variation unrelated to the treatment, the so-called regression to the mean 
(McDonald, et al., 1983). To prevent a spurious statistical artefacts, experimenters should 
control for errors in measuring the outcome variable. Therefore in placebo pain trials with 
subjective reported outcomes it is crucial to check for within patient variation.  
Now, if we are to decompose further the placebo factors featuring in the IBS trial, 
and the cross-over design proposed by (Dworkin, et al., 2014) is the best option, any 
further refinement of the interventions at play in the trial (needling + interaction script) 
should be standardized enough not just to allow replications of the same experiment, but 
even to perform the same intervention more than once during the experiment. I am going 
to discuss now to what extent experimentation with patients alone allows us to reach this 
degree of standardization. Let us first examine needling. 
In the IBS trial, there were two weekly sessions of sham acupuncture, in which 
six to eight dummy needles were placed for 20 minutes over pre-determined non-
acupuncture points on the arms, legs and abdomen. Acupuncture was then treated as it 
were already a standardized procedure, but a closer look at the literature on needling 
reveals that, if we wish to decompose further the analgesic effects of acupuncture through 
trials, we need a more rigorous standardization of the technique that experiments alone 
have not yielded. 
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Indeed, needling techniques have been notoriously difficult to standardize in 
RCTs on pain. For a start, there are different theoretical approaches to needling: e.g., 
whereas the old tradition of acupuncture is primarily based on a traditional understanding 
of body energies, contemporary techniques such as dry needling are based on a 
physiological theory about how pain originates in the muscles (Zhou, Ma, & Brogan, 
2015). Dry needling was originally presented as the mechanical use of a hypodermic 
needle (without injecting a solution) thick enough to puncture contraction knots in the 
muscles, the so-called trigger points, the cause of actual pain (Simons, Travell, Simons, 
& Travell, 1999). Having a candidate mechanism to explain the effects of the intervention 
provides, in principle, a more solid basis to standardize the technique (as compared to 
other approaches to needling). Yet, there has been a significant gap between the purported 
physiological mechanisms of pain targeted by dry needling and the diagnostic criteria 
therapists use to identify them by physical examination (e.g., palpation) (Lucas, 
Macaskill, Irwig, Moran, & Bogduk, 2009; Tough, White, Richards, & Campbell, 2007). 
In blinded tests, examiners have obtained a poor inter-examiner diagnostic reliability, not 
succeeding at locating consensually the trigger points to be then punctured (Myburgh, 
Larsen, & Hartvigsen, 2008). This fundamental ambiguity pervades many other elements 
of the intervention: there is no solid consensus as to how many points to needle in each 
patient, how deep and for how long should the needle be inserted and how many times 
should the treatment be repeated (Quintner, Bove, & Cohen, 2015; Tough, White, 
Cummings, Richards, & Campbell, 2009). Dry needling trials have not succeeded either 
at identifying a clear standard between all the candidate techniques, in terms of its 
superior therapeutic effects. To the contrary, the specific effects are absent or small 
(Cummings & White, 2001; Espejo-Antunez, et al., 2017; Tough, et al., 2009). 
Furthermore, lack of standardization makes comparisons between trials difficult : 
e.g.,(Tough, et al., 2009)  examined 1517 studies and found only seven that were of high 
enough quality (according to standard quality scores) for meaningful analysis. 
RCTs on needling therapies are indeed not very conclusive: they usually lack 
methodological quality (measured with a standard scale) and the aggregate results in 
meta-analyses are poor –see (Madsen, Gotzsche, & Hrobjartsson, 2009). A charitable 
interpretation of this apparent failure would be as follows. If replicability signals a solid 
experimental control of the intervention, this lack of conclusive results would be a sign 
of a still preliminary understanding of the causal structure of the phenomenon under 
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study, the mechanisms underlying pain relief through needling. Only a better grasp of the 
physiological processes by which needles trigger the analgesic response will allow a 
precise standardization of the technique. It should establish precise enough thresholds for 
the identification and selection of the piercing points, depth and duration of the needling,  
etc. 
In other words, and this is the relevant point for my argument: experimenting with 
needles on patients alone has not been enough to standardize the technique. Unlike in 
other experimental fields, in needling experimenting based on loose theoretical concepts 
has not yielded regularities that can be exploited for further theorizing on placebos. 
Without a clear standard, it is impossible to advance in the experimental decomposition 
of the needling factor in the placebo effect through multiple-period cross-over trials. 
Unless therapists can perform the needling with a high enough degree of agreement 
(measured in the usual reliability tests), the measurement error will grow unnoticed in the 
multiple treatment rounds necessary to implement the cross-over design. We will not be 
able to grasp the individual variability of treatment responses and introduce further 
refinements in how needles achieve their analgesic effects. 
We should now turn our attention to the second placebo factor revealed in the IBS 
experiment, the scripted interaction, and discuss whether it is possible to standardize it 
enough to decompose it further. 
4. Standardizing interaction scripts 
The patient-practitioner relationship was implemented in two forms in the IBS 
trial. In the limited interaction arm, the script was described as follows 
The limited patient-practitioner relationship was established at the initial visit 
(duration <5 minutes) during which practitioners introduced themselves and stated 
they had reviewed the patient’s questionnaire and “knew what to do.” They then 
explained that this was “a scientific study” for which they had been “instruc ted 
not to converse with patients.” The placebo needles were then placed, and the 
patient left alone in a quiet room for 20 minutes, a common acupuncture practice, 
after which the practitioner returned to remove the “needles.” 
 In the augmented interaction arm, the description reads: 
Unlike participants in group 2 (limited), however, [the participants] received an 
augmented patient-practitioner relationship that began at the initial visit (45 
minutes duration) and was structured with respect to both content (four primary 
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discussions) and style (five primary points). Content included questions 
concerning symptoms, how irritable bowel syndrome related to relationships and 
lifestyle, possible non-gastrointestinal symptoms, and how the patient understood 
the “cause” and “meaning” of his or her condition. The interviewer incorporated 
at least five primary behaviours including: a warm, friendly manner; active 
listening (such as repeating patient’s words, asking for clarifications); empathy 
(such as saying “I can understand how difficult IBS must be for you”); 20 seconds 
of thoughtful silence while feeling the pulse or pondering the treatment plan; and 
communication of confidence and positive expectation (“I have had much positive 
experience treating IBS and look forward to demonstrating that acupuncture is a 
valuable treatment in this trial”). We based this intervention model on research 
concerning an optimal patient-practitioner relationship. Only after completing this 
nine item agenda did the acupuncturist place the placebo needles and leave the 
participant in a quiet room for 20 minutes. On returning, the practitioner 
“removed” the placebo needles and exchanged a few words of encouragement.  
The participants were not told that the study included two different degrees of 
interaction until the trial ended, so their blinding regarding this particular goal of the 
experiment was not tested. The augmented interaction script incorporated a bundle of 
micro-interventions targeting the patients, for which “future investigations will have to 
determine the relative importance”. My question is whether RCTs alone can unbundle 
this script and establish the relative contribution of its sub-components. My conjecture is 
again pessimist, although for a different reason. Whereas the standardization of needling 
treatments might be achieved through basic research, the standardization of interaction 
scripts seems intrinsically more difficult. On the one hand, as of today, there is no 
fundamental discipline providing the fine grain causal structure of these sort of 
interactions. As I mentioned in the introduction, most experimental social sciences do not 
rely on a fundamental theory to grasp the causal variables, but they are grasped and 
refined through their experimental setups. On the other hand, the more complicated the 
script, the more difficult it is to blind it and fend off the participants’ reactivity. Let me 
start with the former. 
Decomposing the interaction scripts in the IBS so they can be further developed 
into a multiple-period cross-over trial poses the same sort of problems that we already 
witnessed in needling. The causal structure of the intervention is rough: just as the 
insertion technique of the needle was defined with relatively broad margins of precision, 
the interaction script is general enough to admit countless variations. Think for instance 
of the experimenter’s characteristics (gender, age, etc.): without a theory guiding the 
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selection of the relevant factors, a further decomposition of the script would imply 
sampling any number of experimenter characteristics and randomizing the allocation in 
search of potential placebo components. This is, of course, unfeasible and, just as it 
happened with needling techniques, in most social sciences experimenting with 
interaction scripts, the alternative is to try to intervene with this degree of causal 
roughness in search of phenomena. Some fields have indeed accumulated a catalogue of 
relatively robust experimental regularities (e.g., experimental economics (Camerer, et al., 
2016)). Yet some other fields targeting loose interactions, like psychology (and, in 
particular, social psychology), have experimented the same proliferation of non-
replicable findings that we already witnessed in acupuncture (Collaboration, 2015). 
For instance, unconscious thought theory is a recent approach in psychology that 
vindicates the superiority of unconscious processes in solving different tasks. Although it 
gained a certain momentum during the last decade, a recent meta-analysis and replication 
study found that the experimental effects observed “concern nothing but spurious effects 
obtained with an unreliable paradigm” (Nieuwenstein, et al., 2015). The interesting point 
is that the authors conducting the replications identified in the literature, at least, 12 
different general factors (each of which with different sub-specifications) that might 
contribute to the outcome, not all of them implemented in the designs examined (Strick, 
et al., 2011). This lack of agreement between the relevant factors contributing to the 
experimental outcome is probably behind the high statistical heterogeneity detected in the 
meta-analyses of experimental psychology: the variation observed between treatment 
effects across studies suggests that there is something other than chance causing it 
(Stanley, Carter, & Doucouliagos, 2018) 
The 45 minutes interaction in the IBS is a bundle of interventions rather than a 
single distinctive script: its nine items (four sets of questions plus five styles of engaging 
behaviour) are surely candidates for separate decomposition in further trials, so that the 
contribution of each sub-factor in the exchange can be assessed separately. The challenge 
is, of course, to formulate each one of them in a standardized enough manner as to secure 
repeatability within the experiment (in the multiple period cross-over design discussed 
before) and replicability of the trial itself. Short of a theory to rely on for the 
standardization of these items, we may wonder how placebo research would succeed in 
standardizing these scripts where many other psychological disciplines seem to have 
failed.  
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An immediate rejoinder would be denying the necessity of any further 
standardization: if the 45 minutes interaction triggers the effect, maybe there is nothing 
else to decompose: if this long script is enough to augment the therapeutic effect of the 
needles in a replicable manner, that is enough for consolidating the placebo effect as a 
phenomenon. Yet interactions this long and so lightly standardized risk to trigger a well-
known source of bias in the experimental social sciences: the participants’ reactivity. A 
fundamental assumption in the IBS trial is that the interaction script under study will 
operate in the test just as it would work outside the experiment: the patient’s response 
should not be different in both setups. Yet, the reactivity of the patients to the 
experimental setup has been amply documented in various fields since the 1940s 
(Morawski, 2015). In the 1950s, psychologists became increasingly concerned about the 
“authenticity” of the participants’ responses and developed tests to detect their ability to 
fake them: e.g., giving socially desirable answers instead of manifesting their real beliefs 
or desires. In addition, researchers increasingly adopted precautions not to influence the 
subject’s performance themselves, testing whether the experimenters’ characteristics had 
any influence on the test outcome (Morawski, 2015, pp. 576-581). Standardizing the 
experiment’s tasks in the experiment became a warrant of objectivity: researchers should 
be entirely interchangeable in order to make the intervention the only difference-mak ing 
factor in the experimental setup. Yet, Robert Rosenthal’s studies in the 1950s soon alerted 
about the limits of standardization: the experimenter may be reading his participants 
identical instructions and still treat the comparison groups differently “in subtle ways” 
according to his own expectations about the test outcome (Morawski, 2015, p. 588). 
From the 1970s onwards, blinding both the experimenters and the participants 
regarding the goals of the experiment became the default solution to control for biases 
they may introduce in the outcome. The most radical form of blinding was deception: 
lying to the participants about the true goals of an experiment (ultimately, about the very 
fact that they were part of an experiment) (Korn, 1997). Blinding therefore makes up for 
a lack of standardization.  
Can blinding control for the participants’ reactivity in a long slightly standardized 
script such as the augmented interaction in the IBS trial? In clinical trials of 
pharmacological treatments, blinding is best achieved with, precisely, a placebo 
externally as similar as possible to the true treatment, but without the active princip le. 
The factor to control for are the participants’ preferences about the treatments on trial and 
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how they relate to the treatment outcomes: e.g., if they don’t want the intervention they 
are actually receiving, these preferences should not have any systematic correlation with 
the outcome –(Zizzo, 2010); see, for a trace of this effect, (Luparello, Leist, Lourie, & 
Sweet, 1970). In placebo tests like the IBS trial, the question is whether there is a way to 
blind whatever preferences’ the therapists or the participants may have about the 
interaction script. As the authors themselves admit, they could not separate the effects of 
observation and assessment (Kaptchuk, et al., 2008, p. 1003). Let me elaborate on this 
point. 
There are three possible scenarios. First, neither the therapists nor the participants 
know which interaction script they are having. This would be the perfect analogue of the 
placebo pill, but this is obviously not possible. The second option would be to deceive 
the participants about the existence of alternatives, but there are strong arguments for 
banning deception in the experimental social sciences, and not just for ethical reasons: if 
the participants suspect they are being deceived, the inferences from the trial outcome 
might be easily challenged (Ortmann & Hertwig, 2002) (Hersch, 2015). The third option 
is to do away with the blinding and explicitly disclose the real nature of the scripted 
interaction, as in the so-called open label placebos, and check for whatever impact this 
disclosure may have on the outcome4. Yet, the only outcome variable in which solid 
placebo effects have been detected is a subject reported pain score: patients assess in a 
scale the relief caused by the treatment. This is a variable that is highly sensitive to a 
number of reactivity- linked biases: e.g., the patient’s score may reflect more a desire to 
please an engaging therapist than an actual reduction in pain (Gracely, Dubner, Deeter, 
& Wolskee, 1985). A meta-analysis on trials with subject reported outcomes has 
documented how, if the assessor taking the score is not blinded regarding the treatment 
administered, the score differs from the one obtained in blinded assessments (Savovic, et 
al., 2012). 
In other words, if instead of decomposing and standardizing the interaction script, 
placebo researchers opt for keeping it long and complex, given the outcome variable 
under study, the measurement process may be contaminated by the participants’ 
expectations. It is surely possible to implement additional checks to control for this 
possibility, but, at this point, we should be aware that the sources of error we are trying 
                                                                 
4 As (Kaptchuk, et al., 2010) admit, in the trial of open label placebos, report biases derived from the 
therapist-patient interaction are, in principle, impossible to eliminate. 
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to control for in the decomposition of the IBS trial keep piling up (standardization of the 
needle treatment and the scripted interventions plus reactivity) which is in itself a reason 
for pessimism. It is time to take stock and consider some final objections.  
5. Concluding remarks 
Let us review the whole argument now. I have proposed to take placebo effects as 
experimental regularities, phenomena, until a consensual unified theory explains them all. 
Of all these potential phenomena, I take that placebo effects measured in RCTs are the 
most interesting for medical purposes, since those placebos achieving clinical and 
statistical significance would count as legitimate treatments. Even if its full causal 
structure is not yet understood, there would be evidence enough about their benefits.  
The solid placebo phenomenon acknowledged in the most stringent meta-analys is 
(Hrobjartsson & Gotzsche, 2010) is the treatment with medical devices of pain measured 
with patient-reported outcomes. How should placebo researchers invest their resources 
now? Should they run more trials in search of additional placebo regularities or should 
they instead invest in basic research before engaging in more experimentation? I have 
tried to provide an argument for this second alternative, raising some doubts about the 
possibility of further decomposing the causal structure of placebo interventions in trials. 
The IBS trial provides an insightful decomposition of the factors contributing to placebo 
effects, precisely with the sort of intervention and outcome in which it appears as a 
phenomenon.  
If multiple-period cross-over trials are the best methodology for investigating pain 
treatments, it is dubious that the two factors studied in the IBS trial (needle treatments 
and interaction scripts) can be standardized with enough precision as to allow for solid 
reproductions. On the one hand, even the needling with more solid causal foundations 
have found sustained trouble to standardize the basic points in the intervention, leading 
to RCTs with high heterogeneity and inconclusive results. On the other hand, the 
standardization of interaction scripts has proven problematic even in experimenta l 
disciplines that exclusively focus on such scripts. The source of the problem is probably 
in the lack of agreement on the causal factors at play. Blinding, the default debiasing 
procedure to deal with interfering causes, cannot be properly implemented when the 
intervention under analysis (the interaction script) needs to be run in the open.  
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My conclusion is that placebo research should focus on the basic physiologica l 
mechanisms underlying placebo in order to find guidance for further experimentation, so 
that solid phenomena emerge from the tests. This conclusion, like my entire argument, 
can be proven wrong with just a single (but replicable) experiment documenting a placebo 
effect with lowly standardized interventions. Philosophy is, obviously, not conclusive.  
Let me close with a brief discussion of two global objections to my argument. 
First, some placebo researchers will radically argue that there is no causal structure to 
grasp. The anthropologist Dan Moerman has famously objected that experimenta l 
interventions with the same structure implemented in two different countries yield 
different response rates (Moerman, 2002, p. 125), suggesting a contextual dimension that 
can only be grasped locally investigating the meaning of treatments for each particular 
group of patients. My argument suggests instead that the variability may arise from the 
lack of standardization of the interventions. As a matter of fact, in order to find out the 
part of the variance that emerges from cultural factors, it is a prerequisite to standardize 
the interventions. 
A second objection may be that I adopt unjustifiably high experimental standards: 
most research on pain is not conducted with multiple-period cross-over designs; most 
research on needling and interaction scripts in different fields proceeds with rough 
methodological approaches that nonetheless yield valuable outcomes. RCTs, in 
particular, may be poorly equipped to deal with the nuances of placebo interventions so 
it might be worth trying other experimental designs. All this may be the case, but I would 
not say that any of the fields I have examined has suffered from lack of methodologica l 
pluralism –see again (Miller, et al., 2013) about diversity in placebo research. And yet, 
solid, replicable experimental regularities are not easy to find. As I see it, if placebo 
testing is guided by more solid hypotheses on the underlying mechanisms and more strict 
methodological standards, the outcome is more likely to persuade an already sceptical 
audience (Norton, 2015) than a myriad of experiments of the sort we already see. 
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